RecruitingNCT05955014
Data Collection Protocol for Patients With Von Hippel Lindau Disease
Sponsor
M.D. Anderson Cancer Center
Enrollment
125 participants
Start Date
Aug 24, 2023
Study Type
OBSERVATIONAL
Conditions
Summary
To collect information from patients with vHL disease. Information collected will include data on the status of the disease, any surgeries or therapies patients have received for vHL disease, and quality of life.
Eligibility
Min Age: 18 Years
Inclusion Criteria2
- Presence of genetic confirmation or clinical criteria consistent with vHL disease.
- Ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria1
- Patients with psychiatric illness/social situations that would limit compliance with study requirements.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05955014
Related Trials
Familial Investigations of Childhood Cancer Predisposition
NCT030502681 location
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
NCT0740516424 locations
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
NCT0492407584 locations
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
NCT075572251 location
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
NCT040741351 location